• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

作者信息

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente M J, Nazha A, Santini V, McGraw K L, List A F, Sole F, Sekeres M A, Maciejewski J P

机构信息

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18.

DOI:10.1038/leu.2016.228
PMID:27560106
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5143200/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/5143200/25f76160fc9e/nihms806233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/5143200/25f76160fc9e/nihms806233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d234/5143200/25f76160fc9e/nihms806233f1.jpg

相似文献

1
Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.来那度胺治疗的髓系肿瘤患者反应的分子预测指标
Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18.
2
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).来那度胺治疗的伴有孤立性5号染色体长臂缺失（5q-）的骨髓增生异常综合征患者中TP53突变的患病率、克隆动力学及临床影响：德国骨髓增生异常综合征研究组（GMDS）一项前瞻性多中心研究的结果
Leukemia. 2016 Sep;30(9):1956-9. doi: 10.1038/leu.2016.111. Epub 2016 May 2.
3
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).一项多中心前瞻性II期试验的结果，该试验旨在研究来那度胺对伴有孤立性5号染色体长臂缺失（del(5q)）的骨髓增生异常综合征患者的安全性和有效性（LE-MON 5）。
Leukemia. 2016 Jul;30(7):1580-2. doi: 10.1038/leu.2015.340. Epub 2015 Dec 15.
4
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).来那度胺治疗伴有del(5q)和del(9q)的骨髓增生异常综合征患者的疗效及细胞遗传学完全缓解情况
Leuk Res. 2010 Jul;34(7):e169-72. doi: 10.1016/j.leukres.2009.12.015. Epub 2010 Jan 31.
5
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.对伴有 del(5q)的骨髓增生异常综合征使用来那度胺的反应：细胞遗传学和突变的影响。
Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.
6
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.伴有5号染色体长臂缺失的骨髓增生异常综合征表现出适合诊断和反应监测的特征性免疫表型谱。
Haematologica. 2015 Mar;100(3):e93-6. doi: 10.3324/haematol.2014.115725. Epub 2014 Nov 25.
7
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.免疫调节剂来那度胺和沙利度胺治疗骨髓增生异常综合征：临床实践指南。
Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92. doi: 10.1016/j.critrevonc.2012.07.003. Epub 2012 Aug 15.
8
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).来那度胺治疗伴有孤立性5号染色体长臂缺失的低危骨髓增生异常综合征的波兰经验。
BMC Cancer. 2015 Jul 8;15:508. doi: 10.1186/s12885-015-1444-1.
9
Lenalidomide in myelodysplastic syndromes.
Clin Adv Hematol Oncol. 2008 Apr;6(4):271-2, 311.
10
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.奥地利临床常规中使用来那度胺治疗骨髓增生异常综合征患者
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5.

引用本文的文献

1
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
2
Role of reactive oxygen species in myelodysplastic syndromes.活性氧在骨髓增生异常综合征中的作用。
Cell Mol Biol Lett. 2024 Apr 14;29(1):53. doi: 10.1186/s11658-024-00570-0.
3
Case Report of a DDX41 Germline Mutation in a Family with Multiple Relatives Suffering from Leukemia.一个有多名亲属患白血病的家族中DDX41种系突变的病例报告。

本文引用的文献

1
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.随机 III 期研究：来那度胺对比安慰剂在 RBC 输血依赖型低危非 del(5q) 骨髓增生异常综合征患者中的应用，这些患者不适合或对红细胞生成刺激剂耐药。
J Clin Oncol. 2016 Sep 1;34(25):2988-96. doi: 10.1200/JCO.2015.66.0118. Epub 2016 Jun 27.
2
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.来那度胺治疗对无5q缺失的骨髓增生异常综合征克隆结构的影响。
Blood. 2016 Feb 11;127(6):749-60. doi: 10.1182/blood-2015-04-640128. Epub 2015 Dec 1.
3
Biomedicines. 2023 Dec 27;12(1):64. doi: 10.3390/biomedicines12010064.
4
Favorable outcomes of -mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.使用阿扎胞苷±来那度胺治疗的具有特定突变的骨髓增生异常综合征和低原始细胞计数急性髓系白血病的良好预后。
EJHaem. 2023 Aug 25;4(4):1212-1215. doi: 10.1002/jha2.767. eCollection 2023 Nov.
5
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.骨髓增生异常综合征：2023 年关于诊断、风险分层和治疗的更新。
Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8.
6
Current Understanding of Mutations in Myeloid Neoplasms.对髓系肿瘤中突变的当前认识
Cancers (Basel). 2023 Jan 5;15(2):344. doi: 10.3390/cancers15020344.
7
Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies.遗传性血液系统恶性肿瘤诊断中下一代测序检测质量的停滞不前。
J Genet Couns. 2023 Jun;32(3):744-749. doi: 10.1002/jgc4.1672. Epub 2023 Jan 15.
8
Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.DEAD盒型RNA解旋酶DDX41在造血和白血病发生中的独特作用。
Front Oncol. 2022 Sep 2;12:992340. doi: 10.3389/fonc.2022.992340. eCollection 2022.
9
Molecular Threat of Splicing Factor Mutations to Myeloid Malignancies and Potential Therapeutic Modulations.剪接因子突变对髓系恶性肿瘤的分子威胁及潜在治疗调控
Biomedicines. 2022 Aug 15;10(8):1972. doi: 10.3390/biomedicines10081972.
10
Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process.具有诊断价值的骨髓增生异常综合征（MDS）的细胞遗传学和基因异常：聚焦于信使前体RNA剪接过程
Diagnostics (Basel). 2022 Jul 7;12(7):1658. doi: 10.3390/diagnostics12071658.
Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms.
髓系肿瘤中DDX41的遗传性和体细胞缺陷。
Cancer Cell. 2015 May 11;27(5):658-70. doi: 10.1016/j.ccell.2015.03.017. Epub 2015 Apr 23.
4
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.酪蛋白激酶1A1在5号染色体长臂缺失的骨髓增生异常综合征的生物学特性及靶向治疗中的作用
Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.
5
Recurrent genetic defects on chromosome 7q in myeloid neoplasms.髓系肿瘤中7号染色体长臂上的复发性基因缺陷。
Leukemia. 2014 Jun;28(6):1348-51. doi: 10.1038/leu.2014.25. Epub 2014 Jan 16.
6
Somatic SETBP1 mutations in myeloid malignancies.体细胞 SETBP1 突变与髓系恶性肿瘤。
Nat Genet. 2013 Aug;45(8):942-6. doi: 10.1038/ng.2696. Epub 2013 Jul 7.
7
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).CRBN基因中的A>G多态性可作为无5号染色体长臂缺失的低危/中危-1 MDS患者对来那度胺治疗反应的生物标志物。
Leukemia. 2013 Jul;27(7):1610-3. doi: 10.1038/leu.2013.59. Epub 2013 Feb 26.
8
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.多梳抑制复合物 2 成分在骨髓增生性和骨髓增生异常/骨髓增生性肿瘤中的失活。
Blood. 2012 Feb 2;119(5):1208-13. doi: 10.1182/blood-2011-07-367243. Epub 2011 Nov 3.
9
Frequent pathway mutations of splicing machinery in myelodysplasia.骨髓增生异常综合征中剪接机制的频繁通路突变。
Nature. 2011 Sep 11;478(7367):64-9. doi: 10.1038/nature10496.
10
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.低危伴有 del(5q)的骨髓增生异常综合征中 TP53 突变可预测疾病进展。
J Clin Oncol. 2011 May 20;29(15):1971-9. doi: 10.1200/JCO.2010.31.8576. Epub 2011 Apr 25.